MREO

Mereo BioPharma Group plc (MREO) Business Model Analysis (2026)

Invetso Score: 5.8/10 — Balanced · Last Updated: 2026-09-01

Overall Score

Revenue Model

No meaningful revenue base is reflected in the latest TTM metrics, so the business model remains pre-commercial or highly limited in current monetization.

Valuation is still anchored more to balance-sheet value than sales, with price-to-sales reported at 0 and enterprise value at just 13.6M.

Profitability

TTM margins remain at 0 across gross, operating, EBITDA, pretax, and net profit, indicating no current operating profitability.

Returns are still deeply negative, with ROA at -80.9%, ROE at -74.8%, and ROIC at -111.4%.

Cash Flow

Operating cash flow and free cash flow remain negative, with FCF per share at -0.1577 and FCF yield at -59.43%.

Cash conversion remains poor despite a high current ratio, as operating cash flow ratio is negative and cash flow coverage metrics are not supportive.

Balance Sheet

Liquidity remains strong, with a current ratio of 5.88 and cash ratio of 5.31.

Leverage is still low, with debt-to-equity at 0.036 and debt-to-assets at 0.030, supporting financial flexibility.

Capital Efficiency

Capital efficiency remains weak, with return on invested capital at -111.4% and return on capital employed at -117.7%.

Asset turnover is effectively zero, showing the company is not yet generating meaningful revenue from its asset base.

Sources

  • Company filings (10-K, 10-Q, investor presentations)
  • Financial and market data providers
  • Public news and industry information

🔒 Go Beyond This Framework

This is one of 10 institutional-grade frameworks Invetso runs on Mereo BioPharma Group plc. Unlock the complete analysis — SWOT, Economic Moat, Porter’s Five Forces, Management, PESTLE and the Invetso Quality Score.

Create your free account on Invetso →